**Title:**

**Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial**

**Authors:** Annika Malmströma, Hans Skovgaard Poulsenb, Bjørn Henning Grønbergc, Giuseppe Stragliottod,Steinbjørn Hansene, Thomas Asklundf, Birgitta Holmlundg, Małgorzata Łysiakh, Joseph Dowsetti, Bjarne Winther Kristenseni, Peter Söderkvisth, Johan Rosellj, Roger Henrikssonk for the Nordic Clinical Brain Tumor Study Group (NCBTSG)

**Affiliations during the study:**

aDepartment of Oncology, Linköping University Hospital, 58185 Linköping, Sweden1 ORCID 0000-0001-8410-4939

bDepartment of Oncology, Dept. 5073, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark, phone +45 35456303

email: Hans.Skovgaard.Poulsen@regionh.dk

cDepartment of Cancer Research and Molecular Medicine, NTNU, Norwegian University of Science and Technology, and The Cancer Clinic, St. Olav´s Hospital - Trondheim University Hospital, 7006 Trondheim, Norway, phone +47 47297878

ORCID 0000-0001-5744-1534

email: bjorn.h.gronberg@gmail.com

dDepartment of Neurology, Karolinska University Hospital, 17176 Solna, Sweden, phone +46 8 51772072

email: Giuseppe.Stragliotto@karolinska.se

eDepartment of Oncology, Odense University Hospital, University of Southern Denmark, J. B. Winsløws Vej 15, 5000 Odense, Denmark, phone +45 6145 3988

email: [Steinbjoern.Hansen@rsyd.dk](mailto:Steinbjoern.Hansen@rsyd.dk)

fDepartment of Oncology, Radiumhemmet, Karolinska University Hospital, 17176 Solna, Sweden2

gDepartment of Oncology and Department of Clinical and Experimental Medicine, Linköping University, 58185 Linköping, Sweden, phone +46 10 103 3163

email: Birgitta.Holmlund@regionostergotland.se

hDepartment of Clinical and Experimental Medicine, Linköping University, 58185 Linköping, Sweden, phone (ML) +46 10 103 2699 and (PS) +46 10 103 1708 ORCID 0000-0001-9867-8706 (PS)

email: [Malgorzata.Lysiak@liu.se](mailto:Malgorzata.Lysiak@liu.se) and Peter.Soderkvist@liu.se

iDepartment of Pathology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, J. B. Winsløws Vej 15, 5000 Odense C, Denmark, phone +45 65414807

email: [Joseph.Dowsett@rsyd.dk](mailto:Joseph.Dowsett@rsyd.dk) and Bjarne.Winther.Kristensen@rsyd.dk

jRegional Cancer Center South East Sweden and Department of Clinical and Experimental Medicine, Linköping University, 58185 Linköping, Sweden, phone +46 10 103 2784

ORCID 0000-0002-2342-1348

email: Johan.Rosell@regionostergotland.se

kDepartment of Radiation Sciences & Oncology, Umeå University, 90185 Umeå, Sweden3

**Corresponding author:** Annika Malmström,Department of Advanced Home Care and Department of Clinical and Experimental Medicine, Linköping University, 58185 Linköping, Sweden, phone+46 10 103 0000, fax +46 10 103 4701

Email: Annika.Malmstrom@regionostergotland.se

**Present affiliation:**

1Department of Advanced Home Care and Department of Clinical and Experimental Medicine, Linköping University, 581 85 Linköping, Sweden

email: Annika.Malmstrom@regionostergotland.se

2Department of Radiation Sciences & Oncology, Umeå University, 90185 Umeå, Sweden phone +46 90 7850000

email: Thomas.Asklund@umu.se

3Department of Radiation Sciences & Oncology, Umeå University, 90185 Umeå, and Regional Cancer Center Stockholm Gotland, Box 6909, 10239 Stockholm, Sweden, phone +46 90 7852917

email: [Roger.Henriksson@sll.se](mailto:Roger.Henriksson@sll.se)

**Funding:** This study was supported by an unrestricted grant from Schering-Plough (now Merck), and research grants from Linköping University Hospital for Neuro-research (AM), Lion´s Cancer Foundation and Cancer Foundation Norrland, Umeå, Sweden (AM, RH), LIUCancer (AM, PS, ML), and South-East Sweden FORSS (AM, PS, ML).

**Disclosure of interest:** Schering-Plough (now Merck) supported this trial with study group meetings (RH, AM, HSP, BHG, GS, TA, SH) and travel grants (AM, BHG, GS, TA, SH). Other authors declare no conflict of interest.

**Title:**

**Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial**

**Abstract:**

**Introduction:** A pilot study of temozolomide (TMZ) given before radiotherapy (RT) for anaplastic astrocytoma (AA) and glioblastoma (GBM) resulted in prolonged survival compared to historical controls receiving RT alone. We therefore investigated neoadjuvant TMZ (NeoTMZ) in a randomized trial. During enrolment concomitant and adjuvant radio-chemotherapy with TMZ became standard treatment. The trial was amended to include concurrent TMZ.

**Patients and Methods:** Patients, after surgery for GBM or AA, age ≤ 60 years and performance status (PS) 0-2, were randomized to either 2-3 cycles of TMZ, 200 mg/m2 days 1-5 every 28 days, followed by RT 60 Gy in 30 fractions or RT only. Patients without progressive disease after 2 TMZ cycles, received the 3rd cycle. From March 2005 TMZ 75 mg/m2 was administered daily concomitant with RT. TMZ was recommended first line treatment at progression. Primary endpoint was overall survival and secondary safety.

**Results:** The study closed prematurely after enrolling 144 patients, 103 with GBM and 41 with AA. Median age was 53 years (range 24-60) and 89 (62%) were male. PS was 0-1 for 133 (92%) patients, 53 (37%) had complete surgical resection and 18 (12%) biopsy. Ninety-two (64%) received TMZ concomitant with RT. Seventy-two (50%) were randomized to neoadjuvant treatment. For the whole study population survival was 20.3 months for RT and 17.7 months for NeoTMZ (p=0.76), this not reaching the primary objective. For the preplanned subgroup analysis we found that NeoTMZ AA patients had a median survival of 95.1 months compared to 35.2 months for RT (p=0.022). For patients with GBM, no difference in survival was observed (p=0.10). MGMT and IDH status affected outcome.

**Conclusion:** No advantage of NeoTMZ was noted for the whole study population or subgroup of GBM, while NeoTMZ resulted in 5 years longer median survival for patients diagnosed as AA.

**Trial** ISRCTN45209900

**Keywords:** Randomized trial, anaplastic astrocytoma, glioblastoma, temozolomide before radiotherapy, molecular markers, IDH mutation, MGMT promotor methylation

**Wordcount** 3704 from Introduction through References

**Introduction**

For glioblastoma (GBM) patients concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) is standard treatment [[1](#_ENREF_1)]. For anaplastic astrocytoma, RT or chemotherapy, either TMZ or PCV, have been shown to result in similar outcomes [[2](#_ENREF_2)]. Few studies have examined the benefit of postoperative TMZ before RT, which is safe and feasible [[3](#_ENREF_3), [4](#_ENREF_4)]. Neoadjuvant TMZ can lead to radiosensitization of tumor cells [[5](#_ENREF_5), [6](#_ENREF_6)], can be initiated faster than RT, diminishing the risk of clinical deterioration due to tumor regrowth [[7](#_ENREF_7), [8](#_ENREF_8)], which might thereby reduce the volume to be irradiated. In a pilot study of neoadjuvant TMZ followed by RT for grade 3-4 astrocytoma, median survival exceeded 27 months (Skovgaard, unpublished data, supplement S1), which was superior to historical controls receiving RT only. Therefore the Nordic Clinical Brain Tumor Study Group initiated this randomized trial comparing neoadjuvant TMZ followed by RT to RT alone.

**Patient and methods**

Patients with newly diagnosed, histologically confirmed GBM or AA according to the local pathology department, 18-60 years old, were recruited from 13 oncology departments in Sweden, Norway, Denmark and Finland, if they had a performance status (PS) WHO 0-2, a life expectancy of >3 months and normal organ function defined as platelets ≥100x109/L, hemoglobin >90 g/L, neutrophils ≥1.5x103/mm3 or leucocyte count ≥3.0x109/L, serum creatinine and bilirubin <1.5x upper limit of normal (ULN) and AST/ALT ≤3 x ULN. Men and women of child bearing potential had to use adequate contraception. Exclusion criteria were prior RT or chemotherapy for glioma, previous other malignancy within 5 years of inclusion except radically treated basal or squamous cell carcinoma of the skin or carcinoma in situ, pregnancy or breastfeeding and any condition that would prevent adequate treatment and follow-up. Patients with prior surgery for grade 2 glioma recurring as grade 3 or 4 were eligible.

The study protocol was approved by Ethics Committees of all participating countries. All patients signed written informed consent.

The study was registered ISRCTN45209900.

***Randomization***

Patients were stratified for center and randomized 1:1 to standard RT (SRT) or TMZ followed by RT (NeoTMZ), according to a computer generated code which was available in sealed envelopes. Randomization forms were faxed to the Oncology Centre, Umeå University Hospital, Umeå, Sweden and treatment allocation was returned by fax to the trial center.

***Study treatment***

Study treatment should start within four weeks after surgery. Neoadjuvant TMZ was dosed 200 mg/m2, days 1-5, every 28 days. A radiologic evaluation was performed after TMZ cycle 2 and the third cycle was administered to patients without progressive disease. Treatment was also discontinued for unacceptable toxicity or patient´s wish.

The recommended RT-schedule was 60 Gy in 30 fractions (five fractions á 2 Gy per week), but alternative fractionations, representing standard at the participating center, were accepted.

Planning target volumes were defined from CT or MRI scans, including the tumor volume from the preoperative examination or after NeoTMZ cycle 2, as appropriate. Multiple field technique for optimal dose distribution was used. (RT description: S2)

After March 2005, all patients received a daily dose of TMZ 75 mg/m2 concurrent with RT (concTMZ) [[1](#_ENREF_1)].

No adjuvant TMZ was planned, but recommended at first recurrence.

***Monitoring and follow-up***

Evaluation before inclusion and each cycle of TMZ included physical examination, assessment of PS, adverse events (AEs) and blood tests. For NeoTMZ-patients, a baseline radiologic examination was performed within 10 days of treatment start. During every TMZ cycle, blood counts including neutrophils, were performed days 21-22 and within 72 hours of the next cycle. During concTMZ, patients were monitored according to local practice.

Patients were reassessed one and three months after finalizing RT, and thereafter followed for progression and survival according to local routine. At first relapse TMZ was recommended (200mg/m2 days 1-5 every four weeks). Relapse treatment for patients who had progressed during NeoTMZ was provided at the discretion of the treating physician.

AEs were assessed according to the WHO grading system of toxicity [[9](#_ENREF_9)], except for nausea and vomiting where the National Cancer Institute Common Toxicity Criteria version 2.0 was used. Only grade 3-5 toxicity was reported.

Study data were monitored at each center and collected by an independent company.

***Statistical analyses***

To detect a 16% difference in 2-year survival (from 18% to 34%) with a power of 80% and a two-sided significance level of 5%, 145 evaluable patients were required in each treatment arm. We estimated a drop-out rate of maximum 10% and aimed at enrolling 322 patients.

The primary endpoint was overall survival from the date of randomization. The secondary endpoint was safety. An interim analysis of 2-year survival was planned after inclusion of 145 patients. Analyses were conducted according to Intention-to-treat. Statistical calculations were done with SPSS version 22.0.

According to protocol, survival analyses included the whole study group, subgroups GBM and AA, and treatment without or with concTMZ (early versus late inclusion).

Survival was estimated by the Kaplan-Meier method and a two-sided log-rank test. Hazard ratios (HRs) were calculated by Cox regression, and for pairwise comparisons by log-rank tests. Multivariate analysis for all patients included diagnosis (GBM vs AA), age (≥50 versus <50 years), gender (men vs women), WHO performance score (2 vs 0-1), surgery (complete vs partial vs biopsy), baseline steroids (yes vs no), and treatment arm. An additional multivariate analysis included MGMT promotor methylation status (MGMT) (methylated vs unmethylated tumor) and IDH status (mutated versus wildtype). For comparison between groups, Fischer´s exact test was used. The significance level was p<0.05.

***Methods for molecular markers***

According to 2016 WHO criteria, molecular markers were included for reclassification of tumors [[10](#_ENREF_10)].Representative tumor areas were chosen for TMA construction and DNA extraction (S3).

MGMT was assessed by pyrosequencing [[11](#_ENREF_11)]. Samples with a mean methylation <9% were considered unmethylated, and ≥9% as methylated (Table S1).

IDH1, p53 and ATRX were investigated by immunohistochemistry and IDH1/IDH2 mutations (R132H and R172K, respectively) also by pyro- and dideoxynucleotide termination sequencing [[12](#_ENREF_12), [13](#_ENREF_13)]. 1p/19q codeletions were assessed both by FISH and droplet digital PCR (ddPCR) (Table S2).

**Results**

Between 13th of January 2003 and 21st of May 2008, 145 patients were randomized, after which inclusion was stopped due to slow enrolment. Patients only screened were not registered. One patient, rediagnosed with anaplastic meningioma, was excluded from the intention-to-treat analysis. For five patients previous surgery for low grade glioma was reported. Median age was 53 years. Median follow-up was 20 months. At the date of last follow-up, 1st of March 2014, 124 subjects (86%) had died.

Patient characteristics were well balanced between treatment arms (Table 1).

Planned study treatment was completed by 74% of all patients (n=107, SRT= 69 and NeoTMZ = 38) (Consort diagram: Figure 1). All patients that completed RT, received 54-64 Gy, apart from 12 patients from one center where 52 Gy (36 Gy whole brain plus 16 Gy tumor boost) initially represented their standard and one patient had palliative RT, 34 Gy in 10 fractions, administered.

AA patients had a median age of 46 years. All randomized to NeoTMZ completed 2 cycles and 90% (n=19) 3 cycles of TMZ. All patients completed RT, whereof 76% (n=16) concTMZ. SRT was completed by 90% (n=18), and 65% (n=13) received concTMZ (Figure 1). The difference between treatment arms, regarding concTMZ or not, was not significant (p=0.43).

Median age was 55 years for GBM patients. Of those randomized to NeoTMZ, 96% (n=49) completed 1 cycle of TMZ, 92% (n=47) 2 cycles and 39% (n=20) all three. Eighty percent (n=41) completed RT, being concTMZ for 51% (n=26). For two patients, treatment was not reported. SRT patients started and completed radiotherapy according to schedule in 98% of cases (n=51), which for 69% (n=36) was concTMZ (Figure 1). Administration of concTMZ or not per allocated treatment did not reach significance (p=0.09).

TMZ after completion of radiotherapy was administered to 88 patients (61%) (AA n=22, GBM n=66), for four adjuvant and 84 at progression. AA patients randomized to SRT received in median six cycles of TMZ compared to four for NeoTMZ. For those with GBM the corresponding numbers were six versus three cycles.

***Molecular characteristics***

Tumor tissue was available for 112 patients, 109 for TMA and 107 for DNA, both available in 104 cases, and were analyzed for MGMT, IDH1/2 mutations and 1p/19q co-deletions. To obtain maximal molecular information for key markers, IDH1 expression and mutations were analyzed on TMA and DNA and 1p/19q codeletions where complemented by ddPCR analyses where IHC failed, TMA was missing and for confirmation. All patients included as AA and IDH1 mutated GBM were analyzed for ATRX and p53 (n=34) (Table 2).

IDH1, but no IDH2, mutations (IDHmut) were detected in 20 patients, 4 of these with previous low grade glioma. Seventeen of 31 AA patients harboured IDH1mut and three patients with GBM had IDHmut tumor, probably representing secondary GBM. Two patients with IDH1mut tumor were also 1p/19q codeleted. IDH mutations for AA were evenly distributed between treatment arms (p= 0.074). Fifteen tumors were positive for p53 immunostaining, indicating a p53 mutated tumor, and 10 had loss of ATRX.

***Survival***

Median overall survival (MOS) was 17.7 months (95% CI 13.2-22.3) for NeoTMZ and 20.3 months (95% CI 15.7-25.0) for SRT (p= 0.76, NeoTMZ vs SRT HR= 0.95; 95% CI= 0.66-1.35). Survival for all patients at 24 months (n=144) was 38.9% (95% CI 0.28-0.50) for NeoTMZ and 41.7% (95% CI 0.30-.053) for SRT with overlapping confidence intervals (Figure 2a).

In multivariate analysis (n=142), diagnosis and surgery were significant prognostic factors, while baseline steroids was borderline significant and treatment arm non-significant. (Table 3a). For those analyzed for MGMT and IDH mutation (n=107), MGMT- and IDH status together with baseline steroids were significant for survival, while histological diagnosis was of borderline significance (Table 3b). We found no correlation or interaction between MGMT and IDH status.

We found a significant survival benefit of adding concomitant TMZ in the overall population (p= 0.010) (Figure S1).

***Subgroup analyses***

Among patients randomized as AA (n=41), MOS was 95.1 months (95% CI 52.2-138.0) for NeoTMZ and 35.2 months (95% CI 0-77.7) for SRT (p= 0.022, NeoTMZ vs SRT HR= 0.41; 95% CI 0.19-0.90) (Figure 2b).

For GBM (n=103) there was no significant difference in survival related to treatment arm. MOS was 15.3 months (95% CI 11.6-19.0) for NeoTMZ versus 18.1 months (95% CI 13.9-22.3) for SRT (p= 0.10, NeoTMZ vs SRT HR= 1.40; 95% CI 0.93-2.09) (Figure 2c).

For GBM patients randomized to SRT, harboring methylated tumor MGMT (mMGMT), survival was superior compared to the other three arms (p<0.001) (n=78) (Figure 2d).

Patients with IDH1 mutated tumor (n=20), receiving NeoTMZ, seemed to have longer survival (MOS not reached at 100 months (95% CI cannot be computed) vs SRT 48.8 months (95% CI 41.3-56.3)) but this was not statistically significant (p= 0.27, NeoTMZ vs SRT HR 0.48; 95% CI 0.13-1.81) (Figure 2e).

For 92 patients with IDH1/2 wildtype (wt) glioma there was no difference in survival according to treatment arm, with MOS for NeoTMZ vs SRT being 16.0 months (95% CI 12.7-19.2) and 19.3 months (95% CI 15.9-22.8) respectively, (p= 0.10, NeoTMZ vs SRT HR 1.42; 95% CI 0.93-2.17) (Figure 2f).

For those with IDH1/2wt tumor and MGMT status determined (n=89), survival was superior for SRT patients with mMGMT compared to SRT and uMGMT (p= 0.0040), NeoTMZ and uMGMT (p<0.001) and of borderline significance for NeoTMZ with mMGMT (p= 0.059) (overall p= 0.0026) (Figure S2).

***Safety***

All but 2 patients with AEs ≥3 were treated with TMZ. One patient suffered fatal cerebral hemorrhage 11 days after initiating TMZ, two patients died of MDS/aplastic anemia and four patients developed thromboembolic disease, one being fatal. One patient died of undiagnosed breathing problems. The AEs unrelated to TMZ were seizures, and breast cancer diagnosed 4 years after SRT (Table 4).

**Discussion**

We found no survival advantage for NeoTMZ for the whole study group or the subgroup with GBM. The neoadjuvant treatment was generally well tolerated and did not cause unexpected toxicity.

In the overall cohort, concTMZ prolonged survival compared to RT alone.

In contrast to GBM, for those included as AA patients, neoadjuvant temozolomide achieved 5 years longer median survival. Also, for these patients, TMZ at recurrence and/or concurrent with RT did not appear to compensate for not administering TMZ neoadjuvant, as thirteen of 20 patients in the SRT arm received concTMZ. This might suggest a larger benefit of more extensive up-front TMZ treatment, although these findings need to be interpreted with caution, as the cohort of AA patients included both those with IDHmut and IDHwt tumor and also numbers are small.

For GBM patients, the neoadjuvant treatment did not confer any advantage over SRT, the subgroup of SRT patients with mMGMT having the longest survival. Our data indicate that in GBM patients, start of RT should not be delayed for treatment with TMZ, not even for those with mMGMT. When analyzing the role of MGMT methylation in patients with IDHwt tumors, the same pattern emerged.

In a phase 2 trial, 50 patients with GBM underwent 2 weeks of daily TMZ followed by concomitant hypofractionated accelerated radiotherapy to 60 Gy, followed by adjuvant TMZ. This resulted in a median survival of 22.3 months for the whole study group, and 53.8 months for those with mMGMT versus 16.2 months for uMGMT [[14](#_ENREF_14)]. We are only aware of one randomized study of neoadjuvant TMZ before concurrent TMZ and RT. In this study, where 99 GBM patients were enrolled, a survival benefit for neoadjuvant TMZ was demonstrated (17.6 vs. 13.2 months; p= 0.021). Also in this trial TMZ was administered daily only during fourteen days before chemo-radiotherapy [[15](#_ENREF_15)], this being an important difference compared to our study. These trials indicate that the duration of TMZ before start of RT could be important.

In grade 3 glioma several studies have demonstrated that the addition of chemotherapy improves survival when compared to RT alone. In the CATNON trial (NCT00626990) for anaplastic glioma without 1p/19q co-deletions, patients were randomized between RT with or without TMZ concomitant and/or adjuvant. Preliminary results from ASCO 2016 demonstrated a benefit for the addition of TMZ [[16](#_ENREF_16)]. The molecular background related to this outcome is not yet determined, but it is probable that this trial included both IDHmut and IDHwt patients, as our subgroup of AA patients. Interestingly, CATNON randomized patients to 12 cycles of adjuvant TMZ. As we found a survival benefit for 3 cycles of neoadjuvant TMZ, this could imply that a shorter course of TMZ might be sufficient.

Two large randomized studies (RTOG 9402, EORTC 26951) have evaluated PCV chemotherapy for anaplastic oligodendroglioma, which was shown to confer a major survival benefit compared to RT alone, these studies exploring neoadjuvant (preRT) and adjuvant (postRT) therapy, respectively [[17](#_ENREF_17), [18](#_ENREF_18)]. Both trials reported IDH mutational status being of importance for the effect of PCV [[19](#_ENREF_19)]. In our trial the number of patients with IDH mutated tumor is small, but seems to be in line with previous findings, with a trend towards longer survival for those receiving NeoTMZ treatment.

Our trial has some shortcomings. We did not include the planned number of patients, due to slow accrual. The cohort of AA patients is small, including both IDHmut and wildtype astrocytomas and some potential imbalances between treatment characteristics can be noted, such as IDHmut/wt and concTMZ or not, although none reaching statistical significance, a contribution of these to the survival differences cannot be ruled out. The need for incorporating concomitant TMZ to RT was not foreseen at the time of study initiation in 2003. At this time, molecular differences between subgroups of high grade tumors where not well defined and was not incorporated into the study protocol. Because of the inherent difficulties in glioma grading, we chose to analyze outcome both according to the original histological diagnosis and to include molecular markers, in accordance with the latest classification system for high grade glioma [[10](#_ENREF_10)], the analyses of molecular markers being done post hoc. The small subgroup of patients with IDH mutated tumor does not allow for a statistically solid conclusion.

Our data indicate that neoadjuvant temozolomide for 2-3 cycles before radiotherapy cannot be recommended to high grade glioma in general or the subgroup of GBM, while for those included as AA a substantial survival benefit was noted. If this is caused by IDH mutation may be clarified by the molecular outcome of the CATNON trial.

**Acknowledgement:** Lena Olsson for monitoring and secretarial work and Dr Sara Kinhult for monitoring patients from Malmö, Sweden.

We would like to acknowledge all participating centers, investigators, study nurses and patients who consented to be randomised and the Departments of Pathology that contributed with tissue. (S4)

Preliminary results of this trial were presented at the EANO meeting 2010.

**References**

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005;352:987-96. Epub 2005/03/11.

2. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27:5874-80. Epub 2009/11/11.

3. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncology. 2002;4:261-7. Epub 2002/10/03.

4. Brada M, Ashley S, Dowe A, Gonsalves A, Huchet A, Pesce G, Reni M, Saran F, Wharram B, Wilkins M, Wilkins P. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2005;16:942-9. Epub 2005/05/05.

5. Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. International journal of radiation oncology, biology, physics. 2009;75:212-9. Epub 2009/08/22.

6. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ, Sminia P. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. International journal of radiation oncology, biology, physics. 2007;69:1246-53. Epub 2007/10/31.

7. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The lancet oncology. 2012;13:916-26. Epub 2012/08/11.

8. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro-oncology. 2009;11:842-52.

9. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva

Albany, N.Y.: World Health Organization ;

sold by WHO Publications Centre USA; 1979.

10. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica. 2016;131:803-20.

11. Collins VP, Ichimura K, Di Y, Pearson D, Chan R, Thompson LC, Gabe R, Brada M, Stenning SP, Collaborators BR. Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. Acta Neuropathol Commun. 2014;2:68.

12. Roodakker KR, Elsir T, Edqvist PD, Hagerstrand D, Carlson J, Lysiak M, Henriksson R, Ponten F, Rosell J, Soderkvist P, Stupp R, Tchougounova E, Nister M, Malmstrom A, Smits A. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Oncotarget. 2016.

13. Willander K, Falk IJ, Chaireti R, Paul E, Hermansson M, Green H, Lotfi K, Soderkvist P. Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. Biomark Res. 2014;2:18.

14. Shenouda G, Souhami L, Petrecca K, Owen S, Panet-Raymond V, Guiot MC, Corredor AG, Abdulkarim B. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. International journal of radiation oncology, biology, physics. 2017;97:487-94.

15. Mao Y, Yao Y, Zhang LW, Lu YC, Chen ZP, Zhang JM, Qi ST, You C, Wang RZ, Yang SY, Zhang X, Wang JS, Chen JX, Yang QY, Shen H, Li ZY, Wang X, Ma WB, Yang XJ, Zhen HN, Zhou LF. Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial. Chinese medical journal. 2015;128:2751-8. Epub 2015/10/21.

16. Grimm SA, Chamberlain MC. Anaplastic astrocytoma. CNS Oncol. 2016.

17. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31:337-43.

18. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31:344-50.

19. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ, Jr. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32:783-90.

**Figure 1.** **Consort diagram for all randomized patients**

adeath due to intracerebral bleeding after 1 cycle of TMZ

b1 death after 2 cycles of TMZ

c1 rash and 1 infection

dNo RT, but received 2 cycles of TMZ

eFor treatment arm SRT: full dos RT

fFor NeoTMZ: 3 cycles of TMZ followed by full dose RT

Without recurrence since randomization at last follow-up March 1st 2014:

g77, 87 and 98 months

h90, 95, 96, 96, 103 and 119 months

i102 months

j102 months

**Figure 2a-f. Overall Survival by Kaplan-Meier:** Standard Radiotherapy (SRT) and Neoadjuvant Temozolomide (NeoTMZ)

**Figure 2a.** All patients: SRT (n=72) versus NeoTMZ (n=72).

**Figure 2b.** Anaplastic Astrocytoma (AA): SRT (n=20) versus NeoTMZ (n=21).

**Figure 2c.** Glioblastoma (GBM): SRT (n=52) versus NeoTMZ (n=51).

**Figure 2d.** GBM: SRT unmethylated (n=19) vs SRT methylated (n=24) vs NeoTMZ unmethylated (n=11) vs NeoTMZ methylated (n=24). All patients received TMZ, apart from three in the SRT arm with unmethylated MGMT

**Figure 2e.** IDHmut glioma: SRTa (n=9) versus NeoTMZ (n=11). a2 patients 1p/19q codeleted

**Figure 2f.** IDHwt glioma: SRT (n=50) versus NeoTMZ (n=42).